Morphosys Ag (OP:MPSYF)

73.27 UNCHANGED

Last Price Updated: 3:33 PM EDT, Jul 9, 2024 Add to My Watchlist

Price and Volume

Volume	0
Open	73.27
Bid (Size)	N/A (0)
Ask (Size)	N/A (0)
Prev. Close	73.27
Today's Range	73.27 - 73.27
52wk Range	N/A - N/A
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Merger Squeeze-Out of MorphoSys Minority Shareholders Approved at 2024 Annual General Meeting

August 27, 2024

Via ACCESSWIRE

MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting

April 24, 2024

Via ACCESSWIRE

Performance

More News

MorphoSys' Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis

April 11, 2024

Via ACCESSWIRE

MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act

March 21, 2024

Via ACCESSWIRE

Invitation to MorphoSys' Full Year Results 2023 Conference Call on March 14, 2024

March 07, 2024

Via ACCESSWIRE

Invitation to MorphoSys' Third Quarter and First Nine Months 2023 Financial Results Conference Call on November 16, 2023

November 09, 2023

Via ACCESSWIRE

Invitation to MorphoSys' Full Year Results 2022 Conference Call on March 16, 2023

March 09, 2023

Via ACCESSWIRE

MorphoSys AG: Financial Calendar 2023

November 28, 2022

Via ACCESSWIRE

MorphoSys’ Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer’s Disease

November 14, 2022

Via ACCESSWIRE

MorphoSys to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 07, 2024

Via ACCESSWIRE

Ad hoc: MorphoSys' Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction

November 20, 2023

Via ACCESSWIRE

MorphoSys To Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2023 ASH Annual Meeting

November 02, 2023

Via ACCESSWIRE

MorphoSys Reports Preliminary Q3 2023 Monjuvi U.S. Sales and Gross Margin, and Updates Financial Guidance for 2023

October 25, 2023

Via ACCESSWIRE

MorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer

September 12, 2023

Via ACCESSWIRE

MorphoSys Stops Work and Operations on Pre-Clinical Research Programs

March 02, 2023

Via ACCESSWIRE

Invitation to MorphoSys’ Third Quarter and First Nine Months 2022 Results Conference Call on November 17, 2022

November 10, 2022

Via ACCESSWIRE

MorphoSys Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022

October 21, 2022

Via ACCESSWIRE

Ad hoc: MorphoSys Stops Work and Operations on Pre-Clinical Research Programs and Reduces Workforce at its Germany Headquarters

March 02, 2023

Via ACCESSWIRE

MorphoSys AG: MorphoSys Expects Topline Data from Phase 3 Study of Pelabresib in Myelofibrosis in Early 2024

January 09, 2023

Via ACCESSWIRE

MorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability

January 05, 2023

Via ACCESSWIRE

MorphoSys to Share New Data on Pelabresib and Monjuvi(R) (tafasitamab-cxix) in 14 Presentations at the American Society of Hematology Annual Meeting

November 03, 2022

Via ACCESSWIRE

MorphoSys Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209) Supporting Its Potential Application in a Broad Array of Advanced Tumors

October 27, 2022

Via ACCESSWIRE

MorphoSys AG: Invitation to MorphoSys' Second Quarter and First Half Year 2022 Results Conference Call on August 4 , 2022

July 28, 2022

Via ACCESSWIRE

GSK, MorphoSys' Licensing Partner, Provides Update on ContRAst Phase III Program for Otilimab in Moderate to Severe Rheumatoid Arthritis

October 27, 2022

Via ACCESSWIRE

MorphoSys AG: Invitation to MorphoSys' Second Quarter and First Half Year 2022 Results Conference Call on August 4 , 2022

July 28, 2022

From MorphoSys AG

Via AccessWire

Frequently Asked Questions

Is Morphosys Ag publicly traded?

Yes, Morphosys Ag is publicly traded.

What exchange does Morphosys Ag trade on?

Morphosys Ag trades on the OTC Traded

What is the ticker symbol for Morphosys Ag?

The ticker symbol for Morphosys Ag is MPSYF on the OTC Traded

What is the current price of Morphosys Ag?

The current price of Morphosys Ag is 73.27

When was Morphosys Ag last traded?

The last trade of Morphosys Ag was at 07/09/24 03:33 PM ET